Merck + Co., Inc.

Scynexis, Inc.

Francis P Gailliot

Thomas R Verhoeven

Paul J Reider

Michel M Chartrain

Chris H Senanayake

Brian Heimbuch

F Edward Roberts

Randolph L Greasham

Neal C Connors

Rebecca A Chmielowski

Roger C Olewinski, Jr

Barbara A Jackey

Jennifer M Pollard

Barry C Buckland

Chanyong Lee

Kent Goklen

Lisa M Dietrich

Lisa M Deitrich

The present disclosure relates to processes useful in the isolation and purification of enfumafungin, which is classified as a triterpene glycoside antifungal compound and acts as a glucan synthase inhibitor. Enfumafungin has application in the treatment of conditions caused by fungal infection and is also useful as an intermediate in the preparation of other compounds useful as antifungal agents and/or inhibitors of (1,3)-&#x3b2;-D-glucan synthesis.

Processes for isolation and purification of enfumafungin

A process is disclosed that bioconverts indene to (1S)-amino-(2R)-indanol substantially free of any of its stereoisomers, by the action of a strain of P. putida or Rhodococcus sp., followed by various chemical step(s), e.g., chiral specific crystallization, treatment with strong acid in the presence of acetonitrile.

Conversion of indene to (1S)-amino-(2R)-indanol free of any

Growing community of inventors

Cranford, NJ, United States of America

Francis P Gailliot